
Chemical Biology and Drug Design p. 201 - 207 (2015)
Update date:2022-08-03
Topics:
Joshi, Rohit R.
Barchha, Avinash
Khedkar, Vijay M.
Pissurlenkar, Raghuvir R. S.
Sarkar, Sampa
Sarkar, Dhiman
Joshi, Rohini R.
Joshi, Ramesh A.
Shah, Anamik K.
Coutinho, Evans C.
Our inability to completely control TB has been due in part to the presence of dormant mycobacteria. This also renders drug regimens ineffective and is the prime cause of the appearance of drug-resistant strains. In continuation of our efforts to develop novel antitubercular agents that especially target dormant mycobacteria, a set of 55 new compounds belonging to the pyrimidone class were designed on the basis of CoMFA and CoMSIA studies, and these were synthesized and subsequently tested against both the dormant and virulent BCG strain of M. tuberculosis. Some novel compounds have been identified which selectively inhibit the dormant tuberculosis bacilli with significantly low IC50 values. This study reports the second molecule after TMC-207, having the ability to inhibit tuberculosis bacilli exclusively in its dormant phase. The synthesis was accomplished by a modified multicomponent Biginelli reaction. A classification model was generated using the binary QSAR approach - recursive partitioning (RP) to identify structural characteristics related to the activity. Physicochemical, structural, topological, connectivity indices, and E-state key descriptors were used for generation of the decision tree. The decision tree could provide insights into structure-activity relationships that will guide the design of more potent inhibitors. This paper reports the second molecule after TMC-207, with the ability to inhibit tuberculosis bacilli in its dormant phase. The paper reports molecules with a novel Pyrimidone Scaffold, the synthesis of which was accomplished with a modified multi-component Biginelli reaction. A classification model was generated using recursive partitioning (RP) technique to identify structural characteristics of the molecules with their varying activities.
View MoreContact:+86-021-6989-5597
Address:No.80 Yichuan Rd., Putuo District,Shanghai,P.R.China
VanderArk International Limited
Contact:86-10-82437576
Address:Qing He
Beijing ZhongDaXinHe Chemical Product Co.,Ltd(expird)
Contact:010-52876516
Address:tongzhoubeiyuan
Contact:+86-310-7092106
Address:Quzhou Modern & New Industrial Park, Handan, Hebei 057250, China
HK Vast Medicinal Chemistry Int'l Group Limited(expird)
website:http://www.hkvast.com/
Contact:+86-15000309979
Address:NO.6,Lane 108,Qinzhou Road,Xuhui District,Shanghai
Doi:10.1055/s-0037-1610675
(2019)Doi:10.1039/c1dt11465d
(2012)Doi:10.1021/bi1011496
(2010)Doi:10.1021/om4004708
(2013)Doi:10.1002/ejoc.201100642
(2011)Doi:10.1002/chem.201102096
(2011)